2023

1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

   The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

2. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

   Cancers, Vol. 15, Núm. 5